Spirapril  (Synonyms: SCH 33844)

Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure^[1][2][3].

Spirapril (feeding needle; 10 mg/kg; 3 weeks) decreases alcohol intake in TGM123 mice and dose not reduce the alcohol consumption in TLM mice^[2].
Spirapril shows a 40.2% reduction in ACE activity in brain membrane from treated-mice^[2].
Spirapril can crosses the blood-brain barrier and suppresses the transgene effect in the experiments^[2].
Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

466.61

C₂₂H₃₀N₂O₅S₂

83647-97-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66.  [Content Brief]

  [2]. Maul B, et al. Alcohol consumption is controlled by angiotensin II. FASEB J. 2001 Jul;15(9):1640-2.  [Content Brief]

  [3]. Olivetti G, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):362-70.  [Content Brief]